{
    "pmid": "34083238",
    "pmcid": "PMC8416776",
    "title": "FDA Approval Summary: Pembrolizumab for the treatment of tumor mutational burden-high solid tumors",
    "authors": [
	"Leigh Marcus",
	"Lola A. Fashoyin-Aje",
	"Martha Donoghue",
	"Mengdie Yuan",
	"Lisa Rodriguez",
	"Pamela S. Gallagher",
	"Reena Philip",
	"Soma Ghosh",
	"Marc R. Theoret",
	"Julia A. Beaver",
	"Richard Pazdur",
	"Steven J. Lemery"
    ],
    "date": 1,
    "month": 9,
    "year": 2021,
    "journal": "Clinical cancer research",
    "url": "https://aacrjournals.org/clincancerres/article/27/17/4685/671619/FDA-Approval-Summary-Pembrolizumab-for-the",
    "doi": "10.1158/1078-0432.CCR-21-0327",
    "license": "This is a U.S. Government work. There are no restrictions on its use."
}
